The market size of Sepsis is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi and others…
[Nevada, United States] – DelveInsight’s “Sepsis Market Insights, Epidemiology, and Market Forecast 2034.” report offers a detailed examination of Sepsis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To Know in detail about the Sepsis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sepsis Market Forecast
Key Findings from the Sepsis Market Report:
-
The Sepsis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
-
In August, 2024: Grand Medical Pty Ltd. announced that their Phase 2 study aims to evaluate the efficacy, safety, and pharmacokinetic characteristics of STC314 injection in sepsis patients receiving loading dose and continuous intravenous infusion, determine the optimal therapeutic dose, and provide supporting evidence for phase III clinical trials.
-
In August, 2024: Vivacelle Bio announced that the purpose of their study is to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
-
In August, 2024: Novartis announced that the purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis -associated acute kidney injury (SA-AKI).
-
In May, 2024: Novartis announced that the purpose of their study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile and to evaluate the safety and tolerability of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis -associated acute kidney injury (SA-AKI).
-
Key Sepsis Companies are as follows: La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals
-
Key Sepsis Therapies that have been identified are: Giapreza, Vasostrict, Onoact Injection (Landiolol hydrochloride), VBI-S, Nangibotide, Allocetra, Adrecizumab, Fetroja/Fetcroja (Cefiderocol), Recomodulin (ART-123), Recombinant human alkaline phosphatase, CER -001, CYT107, Esmolol, BIO-11006.
-
Launching multiple stage Sepsis pipeline products is expected to revolutionize market dynamics, further propelling market growth.
Sepsis Overview:
Sepsis is a life-threatening organ dysfunction that results from the body’s response to infection. If not recognized early and managed promptly, it can lead to septic shock, multiple organ failure and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries where it represents a major cause of maternal and neonatal morbidity and mortality.
Sepsis Drugs Uptake and Pipeline Development Activities:
The drug uptake section highlights the rate at which newly launched or soon-to-be-launched drugs are adopted during the study period. The report includes data on market uptake by drugs, patient uptake by therapies, and sales figures for each drug. Furthermore, it offers insights into Fabry Disease Pipeline Development Activities, examining therapeutic candidates at various stages and the key companies involved.
Sepsis Therapies and Key Companies:
-
Giapreza: La Jolla Pharmaceuticals
-
Vasostrict: Par Pharmaceutical
-
Onoact Injection (Landiolol hydrochloride): Ono Pharmaceutical
-
VBI-S: Vivacelle Bio
-
Nangibotide (LR12): Inotrem
-
Allocetra: Enlivex Therapeutics
-
Adrecizumab: Adrenomed
-
Fetroja/Fetcroja (Cefiderocol): Shionogi
-
Recomodulin (ART-123): Asahi Kasei Pharma Corp.
-
Recombinant human alkaline phosphatase: AM-Pharma
-
CER-001: ABIONYX Pharma
-
CYT107: Revimmune
-
Esmolol (esmolol hydrochloride): Baxter Healthcare Corporation
-
BIO-11006: BioMarck Pharmaceuticals
For more information about Sepsis companies working in the treatment market, visit Sepsis Clinical Trials
Sepsis Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Sepsis.
Sepsis Epidemiology Segmentation:
The Sepsis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalence of Sepsis
-
Prevalent Cases of Sepsis by severity
-
Gender-specific Prevalence of Sepsis
-
Diagnosed Cases of Episodic and Chronic Sepsis
Sepsis Market Drivers
-
Rising incident population
-
Technological advancements
-
Increased funding for new drug development and clinical trials
-
Increasing awareness among common people
-
Increasing research activities during the forecast period.
Scope of the Sepsis Market Report:
-
Study Period: 2020–2034
-
Coverage: 7MM (The United States, EU5, and Japan)
-
Key Sepsis Companies: La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals
-
Key Sepsis Therapies: Giapreza, Vasostrict, Onoact Injection (Landiolol hydrochloride), VBI-S, Nangibotide, Allocetra, Adrecizumab, Fetroja/Fetcroja (Cefiderocol), Recomodulin (ART-123), Recombinant human alkaline phosphatase, CER-001, CYT107, Esmolol, BIO-11006
-
Sepsis Therapeutic Assessment: Current marketed and emerging therapies
-
Sepsis Market Dynamics: Sepsis Market drivers and Sepsis barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Sepsis Unmet Needs: Insights into unmet needs, KOL’s views, Analyst’s views, Market Access, and Reimbursement.
To access the full report and gain a deeper understanding of Sepsis market outlook, drug uptake, treatment scenario, and epidemiology trends, Sepsis Market Forecast
About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.
Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432 , Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com /consulting